Report Detail

Medical Industry Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, Status and Forecast 2020-2026

  • RnM3943881
  • |
  • 04 April, 2020
  • |
  • Global
  • |
  • 96 Pages
  • |
  • QYResearch
  • |
  • Medical Industry

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the AI to Novel Coronavirus (COVID-19) and Epidemic market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the AI to Novel Coronavirus (COVID-19) and Epidemic industry.
Based on our recent survey, we have several different scenarios about the AI to Novel Coronavirus (COVID-19) and Epidemic YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of AI to Novel Coronavirus (COVID-19) and Epidemic will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global AI to Novel Coronavirus (COVID-19) and Epidemic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global AI to Novel Coronavirus (COVID-19) and Epidemic market in terms of revenue.
Players, stakeholders, and other participants in the global AI to Novel Coronavirus (COVID-19) and Epidemic market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global AI to Novel Coronavirus (COVID-19) and Epidemic market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global AI to Novel Coronavirus (COVID-19) and Epidemic market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global AI to Novel Coronavirus (COVID-19) and Epidemic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global AI to Novel Coronavirus (COVID-19) and Epidemic market.
The following players are covered in this report:
Google
Alibaba
Artificial Intelligence in Medical Epidemiology
BlueDot
Beijing Infervision Technology Co., Ltd.
BenevolentAI
SenseTime
Insilico Medicine
DEARGEN
Iktos
SRI Biosciences
AI to Novel Coronavirus (COVID-19) and Epidemic Breakdown Data by Type
AI Tracking
AI Predict
AI Recognition
Other
AI to Novel Coronavirus (COVID-19) and Epidemic Breakdown Data by Application
Medical
Public Emergency
Other


1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by AI to Novel Coronavirus (COVID-19) and Epidemic Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 AI Tracking
    • 1.4.3 AI Predict
    • 1.4.4 AI Recognition
    • 1.4.5 Other
  • 1.5 Market by Application
    • 1.5.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Share by Application: 2020 VS 2026
    • 1.5.2 Medical
    • 1.5.3 Public Emergency
    • 1.5.4 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): AI to Novel Coronavirus (COVID-19) and Epidemic Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the AI to Novel Coronavirus (COVID-19) and Epidemic Industry
      • 1.6.1.1 AI to Novel Coronavirus (COVID-19) and Epidemic Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and AI to Novel Coronavirus (COVID-19) and Epidemic Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for AI to Novel Coronavirus (COVID-19) and Epidemic Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 AI to Novel Coronavirus (COVID-19) and Epidemic Market Perspective (2015-2026)
  • 2.2 AI to Novel Coronavirus (COVID-19) and Epidemic Growth Trends by Regions
    • 2.2.1 AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 AI to Novel Coronavirus (COVID-19) and Epidemic Historic Market Share by Regions (2015-2020)
    • 2.2.3 AI to Novel Coronavirus (COVID-19) and Epidemic Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 AI to Novel Coronavirus (COVID-19) and Epidemic Market Growth Strategy
    • 2.3.6 Primary Interviews with Key AI to Novel Coronavirus (COVID-19) and Epidemic Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top AI to Novel Coronavirus (COVID-19) and Epidemic Players by Market Size
    • 3.1.1 Global Top AI to Novel Coronavirus (COVID-19) and Epidemic Players by Revenue (2015-2020)
    • 3.1.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Concentration Ratio
    • 3.2.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in 2019
  • 3.3 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players Head office and Area Served
  • 3.4 Key Players AI to Novel Coronavirus (COVID-19) and Epidemic Product Solution and Service
  • 3.5 Date of Enter into AI to Novel Coronavirus (COVID-19) and Epidemic Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Historic Market Size by Type (2015-2020)
  • 4.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Forecasted Market Size by Type (2021-2026)

5 AI to Novel Coronavirus (COVID-19) and Epidemic Breakdown Data by Application (2015-2026)

  • 5.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)
  • 5.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America AI to Novel Coronavirus (COVID-19) and Epidemic Market Size (2015-2020)
  • 6.2 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players in North America (2019-2020)
  • 6.3 North America AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Type (2015-2020)
  • 6.4 North America AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe AI to Novel Coronavirus (COVID-19) and Epidemic Market Size (2015-2020)
  • 7.2 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players in Europe (2019-2020)
  • 7.3 Europe AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Type (2015-2020)
  • 7.4 Europe AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)

8 China

  • 8.1 China AI to Novel Coronavirus (COVID-19) and Epidemic Market Size (2015-2020)
  • 8.2 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players in China (2019-2020)
  • 8.3 China AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Type (2015-2020)
  • 8.4 China AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan AI to Novel Coronavirus (COVID-19) and Epidemic Market Size (2015-2020)
  • 9.2 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players in Japan (2019-2020)
  • 9.3 Japan AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Type (2015-2020)
  • 9.4 Japan AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia AI to Novel Coronavirus (COVID-19) and Epidemic Market Size (2015-2020)
  • 10.2 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Type (2015-2020)
  • 10.4 Southeast Asia AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)

11 India

  • 11.1 India AI to Novel Coronavirus (COVID-19) and Epidemic Market Size (2015-2020)
  • 11.2 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players in India (2019-2020)
  • 11.3 India AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Type (2015-2020)
  • 11.4 India AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America AI to Novel Coronavirus (COVID-19) and Epidemic Market Size (2015-2020)
  • 12.2 AI to Novel Coronavirus (COVID-19) and Epidemic Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Type (2015-2020)
  • 12.4 Central & South America AI to Novel Coronavirus (COVID-19) and Epidemic Market Size by Application (2015-2020)

13Key Players Profiles

  • 13.1 Google
    • 13.1.1 Google Company Details
    • 13.1.2 Google Business Overview and Its Total Revenue
    • 13.1.3 Google AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.1.4 Google Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020))
    • 13.1.5 Google Recent Development
  • 13.2 Alibaba
    • 13.2.1 Alibaba Company Details
    • 13.2.2 Alibaba Business Overview and Its Total Revenue
    • 13.2.3 Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.2.4 Alibaba Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.2.5 Alibaba Recent Development
  • 13.3 Artificial Intelligence in Medical Epidemiology
    • 13.3.1 Artificial Intelligence in Medical Epidemiology Company Details
    • 13.3.2 Artificial Intelligence in Medical Epidemiology Business Overview and Its Total Revenue
    • 13.3.3 Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.3.4 Artificial Intelligence in Medical Epidemiology Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.3.5 Artificial Intelligence in Medical Epidemiology Recent Development
  • 13.4 BlueDot
    • 13.4.1 BlueDot Company Details
    • 13.4.2 BlueDot Business Overview and Its Total Revenue
    • 13.4.3 BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.4.4 BlueDot Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.4.5 BlueDot Recent Development
  • 13.5 Beijing Infervision Technology Co., Ltd.
    • 13.5.1 Beijing Infervision Technology Co., Ltd. Company Details
    • 13.5.2 Beijing Infervision Technology Co., Ltd. Business Overview and Its Total Revenue
    • 13.5.3 Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.5.4 Beijing Infervision Technology Co., Ltd. Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.5.5 Beijing Infervision Technology Co., Ltd. Recent Development
  • 13.6 BenevolentAI
    • 13.6.1 BenevolentAI Company Details
    • 13.6.2 BenevolentAI Business Overview and Its Total Revenue
    • 13.6.3 BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.6.4 BenevolentAI Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.6.5 BenevolentAI Recent Development
  • 13.7 SenseTime
    • 13.7.1 SenseTime Company Details
    • 13.7.2 SenseTime Business Overview and Its Total Revenue
    • 13.7.3 SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.7.4 SenseTime Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.7.5 SenseTime Recent Development
  • 13.8 Insilico Medicine
    • 13.8.1 Insilico Medicine Company Details
    • 13.8.2 Insilico Medicine Business Overview and Its Total Revenue
    • 13.8.3 Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.8.4 Insilico Medicine Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.8.5 Insilico Medicine Recent Development
  • 13.9 DEARGEN
    • 13.9.1 DEARGEN Company Details
    • 13.9.2 DEARGEN Business Overview and Its Total Revenue
    • 13.9.3 DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.9.4 DEARGEN Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.9.5 DEARGEN Recent Development
  • 13.10 Iktos
    • 13.10.1 Iktos Company Details
    • 13.10.2 Iktos Business Overview and Its Total Revenue
    • 13.10.3 Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 13.10.4 Iktos Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 13.10.5 Iktos Recent Development
  • 13.11 SRI Biosciences
    • 10.11.1 SRI Biosciences Company Details
    • 10.11.2 SRI Biosciences Business Overview and Its Total Revenue
    • 10.11.3 SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Introduction
    • 10.11.4 SRI Biosciences Revenue in AI to Novel Coronavirus (COVID-19) and Epidemic Business (2015-2020)
    • 10.11.5 SRI Biosciences Recent Development

14Analyst's Viewpoints/Conclusions

    15Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Summary:
    Get latest Market Research Reports on AI to Novel Coronavirus (COVID-19) and Epidemic. Industry analysis & Market Report on AI to Novel Coronavirus (COVID-19) and Epidemic is a syndicated market report, published as Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of AI to Novel Coronavirus (COVID-19) and Epidemic market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,500.00
    $7,000.00
    2,772.00
    5,544.00
    3,241.00
    6,482.00
    529,725.00
    1,059,450.00
    291,900.00
    583,800.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report